Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Thyroid hormone responsive (THRSP) is a nuclear protein that plays a key role in the regulation of lipid metabolism, specifically by promoting de novo fatty acid synthesis in tissues with active lipogenesis such as liver, adipose tissue, and lactating mammary gland[3][4]. THRSP is regulated by thyroid hormone, glucose, insulin, and nutritional factors, and its expression is notably high during periods of metabolic demand, such as lactation. In cancer, particularly breast cancer, elevated THRSP (Spot14/S14) expression correlates with poor prognosis and a more lipogenic tumor phenotype. In addition, dysregulation of THRSP may contribute to conditions such as obesity and hepatic steatosis. Although it does not act as a classical enzyme, receptor, or transporter, THRSP is considered a relevant target and biomarker in cancer and metabolic disease contexts[3][4][2][1].
Not applicable; no clinically approved drugs directly target THRSP. Putative therapeutic targeting would involve modulation of de novo lipogenesis or fatty acid synthesis pathways[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Thyroid hormone responsive (THRSP).